Effects of different doses of triazolam in the middle-of-the-night insomnia: a double-blind, randomized, parallel group study

L Ferini Strambi, Sara Marelli, M Zucconi, Andrea Galbiati, Giovanni Biggio

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

It has been reported that insomnia characterized by difficulty returning to sleep following a nocturnal awakening, otherwise defined as the middle-of-the-night (MOTN) insomnia, is a common form of insomnia in adults with growing prevalence by increasing age. The aim of this study is to evaluate the efficacy and safety of different dosages of triazolam in insomnia patients when taken after a MOTN awakening with difficulty returning to sleep. In this double-blind, randomized, parallel group study, 24 patients (mean age 41.00 ± 10.40, 10 female and 14 male) affected by MOTN insomnia were enrolled and randomized into three groups according to different dosages of triazolam: group A (0.0625 mg), group B (0.125 mg), and group C (0.250 mg). A significant increment of total sleep time, sleep efficiency and a reduction of wake after sleep onset, number of awakening and non-REM sleep stage 1 was observed in T1 (triazolam) in comparison to T0 (placebo) by means of polysomnographic recording, irrespective of dosage. After 2 weeks of the treatment, insomnia severity significantly improved in all three groups in comparison to baseline without diurnal residual effects. This study demonstrates that low dose of triazolam objectively and subjectively improves the sleep of patients having MOTN insomnia. © 2017 Springer-Verlag Berlin Heidelberg
Original languageEnglish
Pages (from-to)1362-1369
Number of pages8
JournalJournal of Neurology
Volume264
Issue number7
DOIs
Publication statusPublished - 2017

Fingerprint

Triazolam
Sleep Initiation and Maintenance Disorders
Sleep
Sleep Stages
Berlin
Placebos
Safety

Cite this

Effects of different doses of triazolam in the middle-of-the-night insomnia: a double-blind, randomized, parallel group study. / Ferini Strambi, L; Marelli, Sara; Zucconi, M; Galbiati, Andrea; Biggio, Giovanni.

In: Journal of Neurology, Vol. 264, No. 7, 2017, p. 1362-1369.

Research output: Contribution to journalArticle

@article{0ea88d8edee84cc9a3cef32006f07194,
title = "Effects of different doses of triazolam in the middle-of-the-night insomnia: a double-blind, randomized, parallel group study",
abstract = "It has been reported that insomnia characterized by difficulty returning to sleep following a nocturnal awakening, otherwise defined as the middle-of-the-night (MOTN) insomnia, is a common form of insomnia in adults with growing prevalence by increasing age. The aim of this study is to evaluate the efficacy and safety of different dosages of triazolam in insomnia patients when taken after a MOTN awakening with difficulty returning to sleep. In this double-blind, randomized, parallel group study, 24 patients (mean age 41.00 ± 10.40, 10 female and 14 male) affected by MOTN insomnia were enrolled and randomized into three groups according to different dosages of triazolam: group A (0.0625 mg), group B (0.125 mg), and group C (0.250 mg). A significant increment of total sleep time, sleep efficiency and a reduction of wake after sleep onset, number of awakening and non-REM sleep stage 1 was observed in T1 (triazolam) in comparison to T0 (placebo) by means of polysomnographic recording, irrespective of dosage. After 2 weeks of the treatment, insomnia severity significantly improved in all three groups in comparison to baseline without diurnal residual effects. This study demonstrates that low dose of triazolam objectively and subjectively improves the sleep of patients having MOTN insomnia. {\circledC} 2017 Springer-Verlag Berlin Heidelberg",
author = "{Ferini Strambi}, L and Sara Marelli and M Zucconi and Andrea Galbiati and Giovanni Biggio",
year = "2017",
doi = "10.1007/s00415-017-8530-z",
language = "English",
volume = "264",
pages = "1362--1369",
journal = "Journal of Neurology",
issn = "0340-5354",
publisher = "Dr. Dietrich Steinkopff Verlag GmbH and Co. KG",
number = "7",

}

TY - JOUR

T1 - Effects of different doses of triazolam in the middle-of-the-night insomnia: a double-blind, randomized, parallel group study

AU - Ferini Strambi, L

AU - Marelli, Sara

AU - Zucconi, M

AU - Galbiati, Andrea

AU - Biggio, Giovanni

PY - 2017

Y1 - 2017

N2 - It has been reported that insomnia characterized by difficulty returning to sleep following a nocturnal awakening, otherwise defined as the middle-of-the-night (MOTN) insomnia, is a common form of insomnia in adults with growing prevalence by increasing age. The aim of this study is to evaluate the efficacy and safety of different dosages of triazolam in insomnia patients when taken after a MOTN awakening with difficulty returning to sleep. In this double-blind, randomized, parallel group study, 24 patients (mean age 41.00 ± 10.40, 10 female and 14 male) affected by MOTN insomnia were enrolled and randomized into three groups according to different dosages of triazolam: group A (0.0625 mg), group B (0.125 mg), and group C (0.250 mg). A significant increment of total sleep time, sleep efficiency and a reduction of wake after sleep onset, number of awakening and non-REM sleep stage 1 was observed in T1 (triazolam) in comparison to T0 (placebo) by means of polysomnographic recording, irrespective of dosage. After 2 weeks of the treatment, insomnia severity significantly improved in all three groups in comparison to baseline without diurnal residual effects. This study demonstrates that low dose of triazolam objectively and subjectively improves the sleep of patients having MOTN insomnia. © 2017 Springer-Verlag Berlin Heidelberg

AB - It has been reported that insomnia characterized by difficulty returning to sleep following a nocturnal awakening, otherwise defined as the middle-of-the-night (MOTN) insomnia, is a common form of insomnia in adults with growing prevalence by increasing age. The aim of this study is to evaluate the efficacy and safety of different dosages of triazolam in insomnia patients when taken after a MOTN awakening with difficulty returning to sleep. In this double-blind, randomized, parallel group study, 24 patients (mean age 41.00 ± 10.40, 10 female and 14 male) affected by MOTN insomnia were enrolled and randomized into three groups according to different dosages of triazolam: group A (0.0625 mg), group B (0.125 mg), and group C (0.250 mg). A significant increment of total sleep time, sleep efficiency and a reduction of wake after sleep onset, number of awakening and non-REM sleep stage 1 was observed in T1 (triazolam) in comparison to T0 (placebo) by means of polysomnographic recording, irrespective of dosage. After 2 weeks of the treatment, insomnia severity significantly improved in all three groups in comparison to baseline without diurnal residual effects. This study demonstrates that low dose of triazolam objectively and subjectively improves the sleep of patients having MOTN insomnia. © 2017 Springer-Verlag Berlin Heidelberg

U2 - 10.1007/s00415-017-8530-z

DO - 10.1007/s00415-017-8530-z

M3 - Article

VL - 264

SP - 1362

EP - 1369

JO - Journal of Neurology

JF - Journal of Neurology

SN - 0340-5354

IS - 7

ER -